

66. (Previously Presented) The process of claim 65, wherein the disease is ovarian or colon cancer

67. (Previously Presented) An isolated polypeptide comprising a member selected from the group consisting of

- (a) an amino acid sequence which has at least 90% identity to SEQ ID NO:4;
- (b) an immunogenic fragment of the amino acid sequence of (a) that matches an aligned contiguous segment of SEQ ID NO:4 with no more than three single amino acid substitutions, deletions or additions; and
- (c) an immunogenic fragment of the amino acid sequence of (a), wherein the immunogenic fragment is at least 90% identical to the aligned contiguous segment of SEQ ID NO:4,

wherein the isolated polypeptide, when administered to a subject, induces an immune response that recognizes a polypeptide having the sequence of SEQ ID NO:4.

68. (Previously Presented) An isolated polynucleotide encoding the polypeptide of Claim 67.

REMARKS

Restriction/Distinct Inventions:

Claims 1-37 were cancelled in the Preliminary Amendment filed on September 26, 2001 and replaced with claims 38-68. Former claims 1-37 and currently pending claim 38 were subject to a seventeen (17) way Restriction Requirement. Applicants hereby elect Group 1 drawn to a polypeptide and elect the currently pending claims 38-45 and 67 which are directed to the same subject matter.

Closing Remarks

Applicants thank the Examiner for the Office Action and believe this response to be a full and complete response to such Office Action. Accordingly, allowance of this application is respectfully submitted.


FEE DEFICIENCY

☒ If an extension of time is deemed required for consideration of this paper, please consider this paper to comprise a petition for such an extension of time; The Commissioner is hereby authorized to charge the fee for any such extension to Deposit Account No. 50-0258.

and/or

☒ If any additional fee is required for consideration of this paper, please charge Account No. 50-0258.

Respectfully submitted,



Teresa O. Bittenbender
Registration No. 47,425

DECHERT LLP
1717 Arch Street
4000 Bell Atlantic Tower
Philadelphia, PA 19103
Phone: (215) 994-2213
Fax: (215) 655-2213